Clinical Trial

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-15 -> 2027-09-15 2026-07-25
minor Completion pushed: 2026-09-15 -> 2028-09-15 2026-07-25
Trial Details
NCT Number NCT06038461
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Neuroendocrine Tumors
Enrollment 40 participants
Start Date 2023-09-15
Primary Completion 2027-09-15 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-24